Would you treat a patients with metastatic squamous cell lung cancer with >/= 50% PDL-1 expression with first line pembrolizumab/carboplatin/paclitaxel combination or with pembrolizumab alone?

Topics: Thoracic Malignancies • Medical Oncology

Keynote 407 recently published data on pembrolizumab +/- chemo for metastatic squamous cell lung cancer. The confidence interval for the group with >/= 50% PDL-1 expression was wide and crossed one. For this group would you be more inclined to treat with first line pembrolizumab alone?

Answer from: Medical Oncologist at Community Practice

This is a great unanswered question in the literature. The soon to open INSIGNIA trial, through the cooperative groups, will try to better address chemoIO vs IO in the high PDL1 setting. Until then, my approach is to use pembrolizumab alone in patients over expressing PDL1 unless they pr...

Comments

Medical Oncologist at Ralph Lauren Center for Cancer Care and Prevention
Thank you!

Medical Oncologist at Florida Cancer Specialists
Would you also apply the same logic for metastatic...

Medical Oncologist at The Janssen Pharmaceutical Companies of Johnson & Johnson
I would. Unless in extremis, I give those patient...

Medical Oncologist at Yuma Regional Medical Center Cancer Center
Is time to response much faster when using combina...

Related Questions